Literature DB >> 9987206

Treatment of bipolar mixed state with olanzapine.

V Sharma1, L Pistor.   

Abstract

OBJECTIVE: An open trial was conducted to determine the efficacy of olanzapine in the treatment of bipolar mixed state. PARTICIPANTS: Nine inpatients at a provincial psychiatric hospital who met the DSM-IV criteria for bipolar I disorder, most recent episode mixed. INTERVENTION: Olanzapine was added to the existing drug regime in patients who had failed to respond to adequate trials of mood stabilizers used alone or in combination with neuroleptics. OUTCOME MEASURES: Patients were administered the Clinical Global Impression (CGI) Scale, the Brief Psychiatric Rating Scale (BPRS) and the Global Assessment of Functioning (GAF) Scale before the initiation of olanzapine. These scales were repeated and patients were rated on the improvement subscale of the CGI at the time of discharge.
RESULTS: Pretreatment means (and standard deviations [SD]) for the CGI scale, BPRS and GAF were 5.7 (1.1), 60.7 (13.7) and 17.8 (7.5), respectively. Post-treatment means and SD for the scales were 1.9 (0.6), 6.3 (3.3) and 71.7 (5.6), respectively. Paired t-tests on all measures indicated significant improvement in symptoms with t = 9.43, p < 0.001 for CGI; t = -13.28, p < 0.001 for BPRS; t = -21.83, p < 0.001 for GAF. The mean improvement subscale score of the CGI was 1.3 (SD 0.5) at discharge.
CONCLUSIONS: Olanzapine was well-tolerated and was effective in the acute treatment of bipolar mixed state.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9987206      PMCID: PMC1188975     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  14 in total

1.  Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder.

Authors:  M M Dwight; P E Keck; S P Stanton; S M Strakowski; S L McElroy
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

2.  Significance of mixed features in acute mania.

Authors:  S Cohen; A Khan; J Robison
Journal:  Compr Psychiatry       Date:  1988 Jul-Aug       Impact factor: 3.735

3.  Sources of lithium resistance in mixed mania.

Authors:  J M Himmelhoch; M E Garfinkel
Journal:  Psychopharmacol Bull       Date:  1986

4.  Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients.

Authors:  J R Calabrese; P J Markovitz; S E Kimmel; S C Wagner
Journal:  J Clin Psychopharmacol       Date:  1992-02       Impact factor: 3.153

5.  Dysphoric mania.

Authors:  J Clothier; A C Swann; T Freeman
Journal:  J Clin Psychopharmacol       Date:  1992-02       Impact factor: 3.153

Review 6.  Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania.

Authors:  S L McElroy; P E Keck; H G Pope; J I Hudson; G L Faedda; A C Swann
Journal:  Am J Psychiatry       Date:  1992-12       Impact factor: 18.112

7.  Correlates of antimanic response to carbamazepine.

Authors:  R M Post; T W Uhde; P P Roy-Byrne; R T Joffe
Journal:  Psychiatry Res       Date:  1987-05       Impact factor: 3.222

8.  Clozapine in the treatment of dysphoric mania.

Authors:  T Suppes; S L McElroy; J Gilbert; E C Dessain; J O Cole
Journal:  Biol Psychiatry       Date:  1992-08-01       Impact factor: 13.382

9.  Dysphoric mania. Clinical and biological correlates.

Authors:  R M Post; D R Rubinow; T W Uhde; P P Roy-Byrne; M Linnoila; A Rosoff; R Cowdry
Journal:  Arch Gen Psychiatry       Date:  1989-04

10.  Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness.

Authors:  M B Keller; P W Lavori; W Coryell; N C Andreasen; J Endicott; P J Clayton; G L Klerman; R M Hirschfeld
Journal:  JAMA       Date:  1986-06-13       Impact factor: 56.272

View more
  2 in total

Review 1.  Olanzapine: a review of its use in the treatment of bipolar I disorder.

Authors:  N Bhana; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Atypical antipsychotics and mood stabilization in bipolar disorder.

Authors:  Paolo Brambilla; Francesco Barale; Jair C Soares
Journal:  Psychopharmacology (Berl)       Date:  2003-02-27       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.